Delving into the Latest Updates on Adenosine Triphosphate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ATPace

Target

Purinergic P2 receptor

Action

agonists

Mechanism

Purinergic P2 receptor agonists

Therapeutic Areas

Cardiovascular DiseasesNervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Alzheimer DiseaseBradycardiaCachexia+ [2]

Originator Organization

Cordex AG

Active Organization-

Inactive Organization

Cordex AG

DSM Biomedical, Inc.

University of Pennsylvania

+ [3]

License Organization-

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H16N5O13P3

InChIKeyZKHQWZAMYRWXGA-KQYNXXCUSA-N

CAS Registry56-65-5

Persistent cough is a distressing symptom for people with respiratory disorders. Patients also often experience an ongoing urge-to-cough that prompts coughing, and which fails to resolve the sensation. Understanding how the brain controls cough and the urge-to-cough could lead to new cough suppressing therapies. The overall objective of this project is to use functional brain imaging (fMRI) to identify brain regions that are involved in the exaggerated urge-to-cough in humans with chronic cough. Our focus will be on the brainstem where information from the airways first arrives in the central nervous system.

Start Date01 Mar 2019

Sponsor / Collaborator

University of Melbourne

[+3]

NCT03738943

/ CompletedEarly Phase 1IIT

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have lower amounts of ATP released from their red blood cells. However, the contribution of ATP to vasodilation in response to exercise and hypoxia is currently unknown due to the lack of an effective ATP receptor antagonist. We aim to determine whether Vitamin B6 or its metabolite, Pyridoxal-5-Phosphate (PLP) is an effective ATP receptor antagonist.

Start Date07 Feb 2019

Sponsor / Collaborator

Colorado State University

NCT02789358

/ CompletedNot ApplicableIIT

A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation. Results of the the plusONE Randomized Multicenter Trial

This study aims to validate a new dosage of cryotherapy based on time to effect in pulmonary vein ablation procedures in patients with paroxysmal atrial fibrillation.

Start Date01 Dec 2015

Sponsor / Collaborator-

100 Clinical Results associated with Adenosine Triphosphate

Login to view more data

100 Translational Medicine associated with Adenosine Triphosphate

Login to view more data

100 Patents (Medical) associated with Adenosine Triphosphate

Login to view more data

121,157

Literatures (Medical) associated with Adenosine Triphosphate

01 Jan 2026·BIOMATERIALS

A multimodal imaging nanobubble enhancing sonodynamic therapy by cell membrane disruption for effective anti-melanoma

Article

Author: Yao, Yongchao ; Feng, Ziyan ; Xiao, Xueyang ; Xiang, Xi ; Hu, Wenchuang ; Qiu, Li ; Qian, Zhiyong ; Wang, Liyun ; Wang, Ziyao ; Tang, Yuanjiao

Sonodynamic therapy (SDT) offers a new, non-invasive therapeutic choice for melanoma. However, direct use of sonosensitizer like chlorin e6 (Ce6) may face problems like poor drug solubility and off-target effects. Besides, using SDT alone may be deficient to treat melanoma. Nanobubbles (NBs) are novel extravascular ultrasound contrast agents with the ability to perform ultrasound-triggered drug delivery. On the other hand, we found that cell membrane disruption therapy is suitable for working synergistically with SDT. In this study, we used quaternary ammonium salts (QAS) to prepare NBs with therapeutic effect. Besides delivering Ce6, QAS NBs can destroy tumor cell membranes using its special structure, thus enhancing the effect of SDT. The resulting Ce6@QAS NBs had excellent ultrasound-triggered imaging effects and photoacoustic (PA) imaging effects both in vivo and in vitro. The effect in killing tumor cells has been confirmed, including the performance to destroy cells by their outer QAS shells, and the generation of reactive oxygen species (ROS) in SDT process. We found that treated tumor cells were induced to undergo immunogenic cell death (ICD). In the Ce6@QAS NBs with ultrasound group, the tumor growth was significantly inhibited, and anti-tumor immunity was activated. These results suggest that Ce6@QAS NBs can achieve physicochemical synergistic antitumor therapy while performing multimodal imaging.

31 Dec 2025·OncoImmunology

Assessment of adenosinergic activity of small extracellular vesicles in plasma of cancer patients and healthy donors

Article

Author: Menchikova, Elizabeth V. ; Jackson, Edwin K. ; Whiteside, Theresa L. ; Najjar, Yana ; Hong, Chang Sook

The adenosinergic pathway converting endogenous ATP to adenosine (ADO) is a major immunosuppressive pathway in cancer. Emerging data indicate that plasma small extracellular vesicles (sEV) express CD39 and CD73 and produce ADO. Using a noninvasive, highly sensitive newly developed assay, metabolism of N⁶-etheno-labeled eATP, eADP or eAMP by ecto-nucleotidases on the external surface of sEV was measured using high pressure liquid chromatography with fluorescence detection. Ecto-nucleotidase activity in sEV isolated from plasma of randomly selected cancer patients and healthy donors (HDs) was compared. Relative to sEV of HDs, sEV from the plasma of melanoma patients metabolized eATP to eADP and eAMP to eADO with significantly greater efficiency. Activities of both CD39 and CD73 were elevated, as determined by the use of pharmacologic inhibitors selective for these enzymes. In contrast, metabolic activity of CD39 and CD73 on sEV isolated from plasma of patients with head and neck cancer was comparable to that of HDs, suggesting that the activity of ecto-nucleotidases on sEV may differ depending on the cancer type or cancer stage. The N⁶-etheno-purine assay measuring contributions of ecto-nucleotidases residing on the surface of sEV to the extracellular ATP to ADO pathway can discriminate cancer patients from HDs, differentiate among different cancer types, and potentially identify patients most likely to benefit from anti-adenosinergic therapy designed to inhibit the adenosine-mediated immune suppression.

31 Dec 2025·Virulence

The sulfur-related metabolic status of Aspergillus fumigatus during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target

Article

Author: Amich, Jorge ; Storer, Isabelle ; Alharthi, Reem ; Al-Shidhani, Reem ; Zhao, Can ; Fortune-Grant, Rachael ; Tabernero, Lydia ; Bromley, Michael ; Sueiro-Olivares, Monica ; Bignell, Elaine ; Bin Shuraym, Hajer ; Scott, Jennifer

Sulfur metabolism is an essential aspect of fungal physiology and pathogenicity. Fungal sulfur metabolism comprises anabolic and catabolic routes that are not well conserved in mammals, therefore is considered a promising source of prospective novel antifungal targets. To gain insight into Aspergillus fumigatus sulfur-related metabolism during infection, we used a NanoString custom nCounter-TagSet and compared the expression of 68 key metabolic genes in different murine models of invasive pulmonary aspergillosis, at 3 time-points, and under a variety of in vitro conditions. We identified a set of 15 genes that were consistently expressed at higher levels in vivo than in vitro, suggesting that they may be particularly relevant for intrapulmonary growth and thus constitute promising drug targets. Indeed, the role of 5 of the 15 genes has previously been empirically validated, supporting the likelihood that the remaining candidates are relevant. In addition, the analysis of gene expression dynamics at early (16 h), mid (24 h), and late (72 h) time-points uncovered potential disease initiation and progression factors. We further characterized one of the identified genes, encoding the cytosolic serine hydroxymethyltransferase ShmB, and demonstrated that it is an essential gene of A. fumigatus, also required for virulence in a murine model of established pulmonary infection. We further showed that the structure of the ligand-binding pocket of the fungal enzyme differs significantly from its human counterpart, suggesting that specific inhibitors can be designed. Therefore, in vivo transcriptomics is a powerful tool for identifying genes crucial for fungal pathogenicity that may encode promising antifungal target candidates.

2

News (Medical) associated with Adenosine Triphosphate

30 Apr 2025

·pharma.economictimes.indiatimes.com

AstraZeneca to scrap trails of Truqap in prostate cancer after interim analysis

Cambridge: UK-pharma major AstraZeneca has announced plans of discontinuing the Phase III trial of its oncology asset Truqap (capivasertib) in prostate cancer , following an interim analysis suggesting that the “drug is unlikely to meet the dual primary endpoints.” As per the information shared by the company, the decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which reviewed data from a pre-specified interim analysis and concluded that the Truqap combination was unlikely to meet the dual primary endpoints— radiographic progression-free survival (rPFS) and overall survival– versus the comparator arm. The drug is being evaluated in the CAPItello-280 Phase III trial in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer . (mCRPC). The Phase III global trial enrolled 1,033 adult patients and the dual primary endpoints of the trial are radiographic progression-free survival (rPFS) and overall survival to be assessed by the investigator and over trial population respectively. As per the company the safety profile for Truqap was consistent with previous trials and will work with investigators to ensure the necessary follow-up with patients. Truqap is a adenosine triphosphate (ATP)-competitive inhibitor approved in the US, EU, Japan, China and several other countries for the treatment of adult patients with HR-positive (or estrogen receptor-positive). In 2024, the drug global sales reported a jump of 10x to $430 million (around ₹370 crore) attributed with the uptake in biomarker altered subgroup of the indication and some benefit in the US in Q4 2024 due to one-off launch stocking of blister pack. By Online Bureau ,

Phase 3Clinical Trial Termination

30 Apr 2025

·pharma.economictimes.indiatimes.com

AstraZeneca to scrap trails of Truqap in prostate cancer after interim analysis

Cambridge: UK-pharma major AstraZeneca has announced plans of discontinuing the Phase III trial of its oncology asset Truqap (capivasertib) in prostate cancer , following an interim analysis suggesting that the “drug is unlikely to meet the dual primary endpoints.” As per the information shared by the company, the decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which reviewed data from a pre-specified interim analysis and concluded that the Truqap combination was unlikely to meet the dual primary endpoints— radiographic progression-free survival (rPFS) and overall survival– versus the comparator arm. The drug is being evaluated in the CAPItello-280 Phase III trial in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer . (mCRPC). The Phase III global trial enrolled 1,033 adult patients and the dual primary endpoints of the trial are radiographic progression-free survival (rPFS) and overall survival to be assessed by the investigator and over trial population respectively. As per the company the safety profile for Truqap was consistent with previous trials and will work with investigators to ensure the necessary follow-up with patients. Truqap is a adenosine triphosphate (ATP)-competitive inhibitor approved in the US, EU, Japan, China and several other countries for the treatment of adult patients with HR-positive (or estrogen receptor-positive). In 2024, the drug global sales reported a jump of 10x to $430 million (around ₹370 crore) attributed with the uptake in biomarker altered subgroup of the indication and some benefit in the US in Q4 2024 due to one-off launch stocking of blister pack. By Online Bureau ,

Phase 3Clinical Trial Termination

100 Deals associated with Adenosine Triphosphate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00171

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tachycardia	Phase 3	-	DSM Biomedical, Inc.	-
Tachycardia	Phase 3	-	Pfizer Inc.	-
Tachycardia	Phase 3	-	Cordex AG	-
Tachycardia	Phase 3	-	University of Pennsylvania	-
Alzheimer Disease	Phase 2	Spain	-	01 Dec 2014
Bradycardia	Phase 2	United States	Cordex Pharma, Inc.	-
Bradycardia	Phase 2	Canada	Cordex Pharma, Inc.	-
Bradycardia	Phase 2	-	Pfizer Inc.	-
Bradycardia	Phase 2	-	DSM Biomedical, Inc.	-
Bradycardia	Phase 2	-	University of Pennsylvania	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03722849 (CTgov)	Not Applicable	Refractory chronic cough	58	Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Chronic Cough Participant)	afhsfeerke(pgxklxmmau) = vaaerxdrvz ykbgfbuhes (shubthqsgj, 0.60) View more	-	22 Aug 2024
				Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Healthy Control Participant)	afhsfeerke(pgxklxmmau) = vfyoxsenlx ykbgfbuhes (shubthqsgj, 0.47) View more